Data / Form D filings / RheumaGen, Inc.
RheumaGen, Inc.: Form D filings
RheumaGen, Inc., a biotechnology company in Denver, CO, filed 4 Form D notices with the SEC between 2022 and 2024. The latest, on April 17, 2024, reports $700,000 sold of a $700,000 offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 200 QUEBEC ST., BLDG. 600, STE. 205, Denver, CO, 80230
- Phone
- (720) 569-0180
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2022
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1942974
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Apr 17, 2024 | New notice | $700,000 | $700,000 | 1 | Apr 5, 2024 | sec.gov | |
| Apr 17, 2024 | New notice | $15,000,000 | $4,906,587 | $10,093,413 | 3 | Apr 4, 2024 | sec.gov |
| May 26, 2023 | New notice | $300,000 | $300,000 | 1 | May 16, 2023 | sec.gov | |
| Oct 18, 2022 | New notice | $2,000,000 | $2,000,000 | 1 | Oct 12, 2022 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Bruce Michael Goodwin | Director | |
| James Brian Hart, Jr. | Executive Officer | |
| Bobak Robert Mozayeni | Executive Officer | |
| Ryan Kane Hart | Executive Officer | |
| Thomas Matthew Fratacci | Director | |
| Brian Matthew Freed | Executive Officer | |
| Richard Anthony Freed, III | Executive Officer, Director |
Other biotechnology companies in Colorado that filed recently
- GelSana Therapeutics, Inc. $4.4 million · Oct 8, 2026
- Renovare Therapeutics, Inc. $100,000 · Oct 2, 2026
- EnteroTrack, LLC $2 million · Sep 25, 2026
- Shiverbright Technologies, Inc. $200,000 · Aug 7, 2026
Every Form D from the week of Apr 15, 2024 · All recent filings in Colorado · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what RheumaGen, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.